EX-10.25



 Exhibit 10.25 
 ARIAD Pharmaceuticals, Inc. 
 Director Compensation Arrangements

 Effective January 1, 2014 and until further modified by the Board of Directors of ARIAD Pharmaceuticals, Inc. (the
“Corporation”), the Corporation’s non-employee directors will receive the compensation set forth below. Non-employee directors do not receive any other compensation for service on the Board of Directors or its committees, other than
reimbursement of reasonable expenses. Directors who are also employees of the Corporation do not receive any additional compensation for their service on the Board of Directors. All equity awards are granted under the Corporation’s 2006 Long
Term Incentive Plan, as amended. 
 Upon initial appointment or election to the Board of Directors, the director will receive a one-time grant
of 75,000 stock options, which will vest over three years in equal amounts on first, second and third anniversaries of the date of grant. The options will have a term of ten years. The exercise price for such options will be the closing price of the
Corporation’s common stock as quoted on the NASDAQ Global Select Market on the date of grant. 
 Each year, the directors will receive
annual cash compensation of $70,000, paid in equal quarterly amounts on or about the last day of each calendar quarter. In lieu of cash, a director may elect to receive the equivalent value in restricted shares of the Corporation’s common stock
on January 31, subject to a lapsing repurchase right as to 25% of the shares on March 31, June 30, September 30 and December 31 of the year of the award. The number of shares will be determined based on the volume weighted average price (VWAP) of
the Corporation’s common stock for the month of December of the prior year. Such election to be paid in shares in lieu of cash must be made by January 15 of each calendar year. Upon initial appointment or election to the Board of Directors, the
annual cash compensation for that year will be prorated beginning on the first day of the fiscal quarter in which he or she was initially appointed or elected and the individual may elect to be paid in shares in lieu of cash if such election is made
within 10 days of election or appointment. If director dies, resigns or is removed during any quarter, he or she shall be entitled to a cash payment (or shares in lieu thereof) on a pro-rated basis through his or her last day of service. 

Each year on January 31, the directors will receive annual equity grants consisting of 25,000 stock options and 12,500 restricted stock units which will
vest as to 25% of the shares on March 31, June 30, September 30 and December 31 of the year of the award. The options will have a term of ten years. The exercise price for such options will be the closing price of the Corporation’s common stock
as quoted on the NASDAQ Global Select Market on the date of grant. 
 The Board of Directors has adopted stock ownership guidelines, to be
phased in over five years, for the non-employee directors and the Corporation’s Chief Executive Officer. The guideline for the non-employee directors is ownership of the Corporation’s common stock with a value of at least three times the
annual cash compensation and the guideline for the Chief Executive Officer is ownership of the Corporation’s common stock with a value of at least six times his base salary.